MIZORIBONE IS EFFECTIVE AGAINST LECLERCIA ADECARBOXYLATA INFECTIONAbstract
Leclercia adecarboxylata is a gram-negative bacillus. L. adecarboxylata has been isolated from various environments, such as food and water, and clinical specimens from patients with various diseases and ailments, such as pyelonephritis and sepsis. Although L. adecarboxylata infections are generally treated with β-lactam antibiotics, the emergence of multidrug-resistant strains reported in recent years has presented a major challenge in the clinical treatment of the infections. Thus, I searched for potential candidate compounds for developing new antibiotics that are effective against multidrug-resistant L. adecarboxylata. In a docking simulation performed to extract an inhibitor of the molecular chaperone GroEL, mizoribine was identified as a “hit.”Notably, when L. adecarboxylata was cultured in a mizoribine-containing medium, its growth was inhibited at mizoribine concentrations of ≥0.63 mmol/L. considering these findings, I propose that mizoribine could serve as an effective new therapeutic agent for L. adecarboxylata infection. In the future, it will be necessary to investigate the effects of mizoribine on other bacterial species.
Department of Clinical Pharmacy, School of Pharmaceutical Sciences, Ohu University, 31-1 Misumido, Tomitamachi-aza, Koriyama, Fukushima, Japan.
09 March 2022
27 April 2022
26 September 2022
01 November 2022